跳至主要内容
临床试验/NCT05764525
NCT05764525已完成3 期

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Laparoscopic Colectomy

Vivozon Pharmaceutical Inc.5 个研究点 分布在 1 个国家目标入组 285 人开始时间: 2021年7月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
285
试验地点
5
主要终点
Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12)

研究概览

简要总结

The purpose of this phase 3 study is to evaluate the efficacy and safety of VVZ-149 Injections for the treatment of postoperative pain following laparoscopic colectomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women who are at least 18 years of age
  • Female subjects who are not pregnant or breastfeeding
  • Subjects undergoing a planned first laparoscopic colectomy
  • Subjects classified in American Society of Anesthesiologists (ASA) risk class of I or II
  • Subjects who report the pain intensity ≥ 5 on the NRS measured after surgery
  • Subjects who have the ability to understand study procedures and communicate clearly with the investigator and staff
  • Subjects who provide written informed consent prior to participation in the study

排除标准

  • Subjects undergoing emergency or unplanned surgery
  • Subjects who had a previous laparoscopic colectomy procedure, or who had any laparoscopic resection procedure
  • Subjects with pre-existing conditions causing preoperative pain at the site of surgery
  • Female subjects who are pregnant or breastfeeding
  • Diagnosis of chronic pain (e.g., persistent pain with the intensity of NRS ≥ 5 at baseline)

研究组 & 干预措施

VVZ-149 Injections

Experimental

干预措施: VVZ-149 Injections (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Time-weighted Sum of Pain Intensity Differences for 12 Hours Post-dose (SPID 12)

时间窗: 0-12 hours post-dose

Pain Intensity (PI) was assessed on an 11-point numerical rating scale from 0 (no pain) to 10 (worst pain imaginable). Time-weighted Sum of Pain Intensity Difference (PID) for 12 hours post-dose (SPID 12) was estimated using the linear trapezoidal rule (L x Hour) with the PI scores assigned from Time 0 to Time 12 hours post-dose using the following formula. The theoretical SPID 12 ranges from 0 to 120. A higher value of SPID indicates greater pain relief. SPID 12 = S \[T(i)-T(i-1)\] × \[PID(i)+PID(i-1)\]/2, when PID(i) =Predose PI-PI at Time i

次要结局

  • Total Number of Patient-controlled Analgesia (PCA) Requests for 12 Hours Post-dose(0-12 hours post-dose)
  • Total Amount of PCA and Rescue Medication Consumption for 12 Hours Post-dose(0-12 hours post-dose)

研究者

发起方
Vivozon Pharmaceutical Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

Efficacy and Safety of VVZ-149 Injections in... | 临床试验